Literature DB >> 11905809

Pharmacogenetics and cancer therapy.

M V Relling1, T Dervieux.   

Abstract

Pharmacogenetics is the study of how genetic variations affect drug response. These variations can affect a patient's response to cancer drugs, for which there is usually a fine line between a dosage that has a therapeutic effect and one that produces toxicity. Gaining better insight into the genetic elements of both the patient and the tumour that affect drug efficacy will eventually allow for individualized dosage determination and fewer adverse effects.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11905809     DOI: 10.1038/35101056

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  44 in total

1.  Quantification of Thiopurine/UVA-Induced Singlet Oxygen Production.

Authors:  Yazhou Zhang; Ashley N Barnes; Xianchun Zhu; Naomi F Campbell; Ruomei Gao
Journal:  J Photochem Photobiol A Chem       Date:  2011-10-15       Impact factor: 4.291

Review 2.  Pharmacogenetics of drug metabolizing enzymes and transporters: effects on pharmacokinetics and pharmacodynamics of anticancer agents.

Authors:  Norman H Lee
Journal:  Anticancer Agents Med Chem       Date:  2010-10-01       Impact factor: 2.505

Review 3.  Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism.

Authors:  Bertrand Rochat
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 4.  Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy.

Authors:  Magnus Ingelman-Sundberg; Cristina Rodriguez-Antona
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-08-29       Impact factor: 6.237

Review 5.  Chronic health conditions in childhood cancer survivors: is it all treatment-related--or do genetics play a role?

Authors:  Saro H Armenian; Smita Bhatia
Journal:  J Gen Intern Med       Date:  2009-11       Impact factor: 5.128

6.  Early chemosensitivity of normal hematopoietic cells and malignant lymphoblasts predicts relapse in childhood acute lymphoblastic leukemia.

Authors:  Tamer H Hassan
Journal:  Oncol Lett       Date:  2010-11-08       Impact factor: 2.967

7.  Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer.

Authors:  Xiaoqun Dong; Li Jiao; Yanan Li; Douglas B Evans; Huamin Wang; Kenneth R Hess; James L Abbruzzese; Donghui Li
Journal:  J Clin Oncol       Date:  2009-02-23       Impact factor: 44.544

8.  Detection of allelic imbalance in the gene expression of hMSH2 or RB1 in lymphocytes from pedigrees of hereditary, nonpolyposis, colorectal cancer and retinoblastoma by an RNA difference plot.

Authors:  Yoshinori Murakami; Kana Isogai; Hiroyuki Tomita; Mika Sakurai-Yageta; Tomoko Maruyama; Akio Hidaka; Kiyoshi Nose; Kokichi Sugano; Akihiro Kaneko
Journal:  J Hum Genet       Date:  2004-10-08       Impact factor: 3.172

9.  Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma.

Authors:  Nadia Barahmani; Sarah Carpentieri; Xio-Nan Li; Tao Wang; Yumei Cao; Laura Howe; Lindsay Kilburn; Murali Chintagumpala; Ching Lau; M Fatih Okcu
Journal:  Neuro Oncol       Date:  2008-10-24       Impact factor: 12.300

Review 10.  Children's Oncology Group's 2013 blueprint for research: survivorship and outcomes.

Authors:  Saro H Armenian; Wendy Landier; Melissa M Hudson; Leslie L Robison; Smita Bhatia
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.